Ethonafide-induced cytotoxicity is mediated by topoisomerase II inhibition in prostate cancer cells.
Ethonafide is an anthracene-containing derivative of amonafide that belongs to the azonafide series of anticancer agents. The lack of cross-resistance in multidrug-resistant cancer cell lines and the absence of a quinone and hydroquinone moiety make ethonafide a potentially less cardiotoxic replacement for existing anthracene-containing anticancer agents. For this study, we investigated the anticancer activity and mechanism of ethonafide in human prostate cancer cell lines. Ethonafide was cytotoxic against three human prostate cancer cell lines at nanomolar concentrations. Ethonafide was found to be better tolerated and more effective at inhibiting tumor growth compared with mitoxantrone in a human xenograft tumor regression mouse model. Mechanistically, we found that ethonafide inhibited topoisomerase II activity by stabilizing the enzyme-DNA complex, involving both topoisomerase IIalpha and -beta. In addition, ethonafide induced a potent G(2) cell cycle arrest in the DU 145 human prostate cancer cell line. By creating stable cell lines with decreased expression of topoisomerase IIalpha or -beta, we found that a decrease in topoisomerase IIalpha protein expression renders the cell line resistant to ethonafide. The decrease in sensitivity to ethonafide was associated with a decrease in DNA damage and an increase in DNA repair as measured by the neutral comet assay. These data demonstrate that ethonafide is a topoisomerase II poison and that it is topoisomerase IIalpha-specific in the DU 145 human prostate cancer cell line.
Pourpak
Alan
A
Department of Pharmacology, Arizona Cancer Center, The University of Arizona, Tucson, AZ 85724, USA.
Landowski
Terry H
TH
Dorr
Robert T
RT
D000818:Animals; D000951:Antigens, Neoplasm / Q000235:genetics / Q000378:metabolism; D000970:Antineoplastic Agents / Q000494:pharmacology; D002453:Cell Cycle / Q000187:drug effects; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D053903:DNA Breaks, Double-Stranded / Q000187:drug effects; D004250:DNA Topoisomerases, Type II / Q000235:genetics / Q000378:metabolism; D043864:DNA, Catenated / Q000378:metabolism; D018105:DNA, Kinetoplast / Q000378:metabolism; D004268:DNA-Binding Proteins / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D000077143:Docetaxel; D006801:Humans; D007546:Isoquinolines / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D008558:Melphalan / Q000494:pharmacology; D051379:Mice; D016513:Mice, SCID; D008942:Mitoxantrone / Q000494:pharmacology; D053644:Naphthalimides / Q000494:pharmacology*; D011471:Prostatic Neoplasms / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D011485:Protein Binding / Q000187:drug effects; D011810:Quinoxalines / Q000494:pharmacology; D034622:RNA Interference; D043823:Taxoids / Q000494:pharmacology; D059005:Topoisomerase II Inhibitors; D023041:Xenograft Model Antitumor Assays
D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D043864:DNA, Catenated; D018105:DNA, Kinetoplast; D004268:DNA-Binding Proteins; D007546:Isoquinolines; D053644:Naphthalimides; D011810:Quinoxalines; D043823:Taxoids; D059005:Topoisomerase II Inhibitors; C118180:XK 469; D000077143:Docetaxel; D008942:Mitoxantrone; D004250:DNA Topoisomerases, Type II; C521335:2-(2'-(dimethylamino)ethyl)-1,2-dihydro-7-ethoxydibenz(de,h)isoquinoline-1,3-dione; D008558:Melphalan